Results 1 to 10 of about 1,206,776 (294)
Association between neoadjuvant paclitaxel dose intensity and outcomes in early triple-negative and HER2-positive breast cancer: a real-world data analysis [PDF]
ESMO Real World Data and Digital OncologyBackground: Reduction of paclitaxel dose intensity (PDI) is frequent during neoadjuvant treatment of high-risk early triple-negative (TN) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), due to toxicity.
C. van Marcke +22 more
doaj +2 more sources
Relative Dose Intensity of Trabectedin and Outcome of Advanced L‐Sarcomas [PDF]
Cancer MedicineBackground Trabectedin, which is approved for advanced soft tissue sarcoma management, has a complex mechanism of action, but can be classified as an alkylating agent.
Stephen Poitureau +12 more
doaj +2 more sources
Retrospective analysis of the impact of dose delay and reduction on outcomes of colorectal cancer patients treated with FOLFIRI‑based treatment [PDF]
PeerJ, 2023 Objectives To determine the relationship between chemotherapy dose delay/reduction with progression-free survival (PFS) and overall survival (OS) in colorectal cancer patients treated with FOLFIRI based first-line chemotherapy in real-world ...
Xia Zhang +7 more
doaj +2 more sources
The dose no longer plays a paramount role in radiotherapy (oncology), but time apparently does
Nowotwory, 2022 Overall 80 clinical data sets (head and neck, breast, lung and prostate) have been selected from the literature (about 10,000 patients) to analyze and compare the importance of the total dose (D) vs. overall therapy time (OTT).
Bogusław Maciejewski +1 more
doaj +1 more source
Frontiers in Oncology, 2022 IntroductionThis multicenter, real-world cohort study aimed to evaluate the effectiveness of early cumulative dose administration and dosing pattern of liposomal irinotecan plus fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with gemcitabine ...
Yung-Yeh Su +31 more
doaj +1 more source
Cancer Medicine, 2023 Background In the phase 2 double‐blind Study 211, a starting dose of lenvatinib 18 mg/day was compared with the approved starting dose of 24 mg/day in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC).
Matthew H. Taylor +16 more
doaj +1 more source
Annals of Oncology, 1993 Background: The rationale for dose intensity is based on pre-clinical observations in experimental model systems of cancer as well as upon retrospective studies correlating the impact of dose intensity upon response rates and survival. Materials and methods: A review has been performed based on trials attempting to compare the effects of two different ...
Ozols, RF +7 more
openaire +4 more sources
Current Oncology, 2021 There is evidence that achieving a dose intensity > 80% in adjuvant colon cancer treatment improves survival. In total, 192 consecutive patients with resected stage III and high-risk stage II colon cancer that received adjuvant chemotherapy were ...
Suganija Lakkunarajah +5 more
doaj +1 more source
Journal of Veterinary Internal Medicine, 2022 Background The recommended doxorubicin (DOX) dose for small dogs is 1 mg/kg. Recent data suggest that DOX‐induced gastrointestinal (GI) toxicosis can be reduced with maropitant treatment. Objectives To investigate the incidence of adverse events (AEs) in
Fukiko Matsuyama +5 more
doaj +1 more source
BMC Cancer, 2022 Background Colorectal cancer remains the second leading cause of cancer death in North America. Fluorouracil and oxaliplatin based adjuvant chemotherapy for resected colon cancer (CC) reduces cancer recurrence, but also causes significant toxicity ...
Daniel Breadner +10 more
doaj +1 more source